Regeneron News and Research

RSS
Regeneron's ARCALYST meets primary, secondary endpoints in second Phase 3 gout flare study

Regeneron's ARCALYST meets primary, secondary endpoints in second Phase 3 gout flare study

Regeneron submits VEGF Trap-Eye BLA to FDA for treatment of wet AMD

Regeneron submits VEGF Trap-Eye BLA to FDA for treatment of wet AMD

Regeneron, Bayer and SERI initiate new VEGF Trap-Eye Phase 3 clinical trial in myopic CNV

Regeneron, Bayer and SERI initiate new VEGF Trap-Eye Phase 3 clinical trial in myopic CNV

FDA stops pain drug trial over safety concerns

FDA stops pain drug trial over safety concerns

Positive top-line results from VEGF Trap-Eye Phase 3 studies in macular edema due to CRVO

Positive top-line results from VEGF Trap-Eye Phase 3 studies in macular edema due to CRVO

Celulas Genetica to submit international patent application for Rutherford Procedure

Celulas Genetica to submit international patent application for Rutherford Procedure

Phase 3 study of VEGF Trap-Eye regimen meets primary endpoint in patients with wet AMD

Phase 3 study of VEGF Trap-Eye regimen meets primary endpoint in patients with wet AMD

Aflibercept Phase 3 VELOUR clinical trial for mCRC to continue to completion

Aflibercept Phase 3 VELOUR clinical trial for mCRC to continue to completion

Astellas extends non-exclusive license agreement with Regeneron for VelocImmune technology

Astellas extends non-exclusive license agreement with Regeneron for VelocImmune technology

Regeneron second-quarter total revenues increase to $115.9 million

Regeneron second-quarter total revenues increase to $115.9 million

Regeneron's ARCALYST prevents gout attacks in Phase 3 study of patients initiating allopurinol therapy

Regeneron's ARCALYST prevents gout attacks in Phase 3 study of patients initiating allopurinol therapy

Regeneron Pharmaceuticals provides update on REGN727, REGN475 antibody product candidates

Regeneron Pharmaceuticals provides update on REGN727, REGN475 antibody product candidates

REGN reports net loss of $30.5M for first-quarter 2010

REGN reports net loss of $30.5M for first-quarter 2010

Phase 2 study results: VEGF Trap-Eye improves vision in patients with DME

Phase 2 study results: VEGF Trap-Eye improves vision in patients with DME

BioMed Realty Trust announces financial results for fourth-quarter and full-year ended December 31, 2009

BioMed Realty Trust announces financial results for fourth-quarter and full-year ended December 31, 2009

sanofi-aventis reports 2009 fourth-quarter and full-year net earnings

sanofi-aventis reports 2009 fourth-quarter and full-year net earnings

6th Annual Diabetes Conference to feature ocular drug delivery in diabetic retinopathy

6th Annual Diabetes Conference to feature ocular drug delivery in diabetic retinopathy

BioMed Realty Trust receives additional space at Landmark under new lease agreement

BioMed Realty Trust receives additional space at Landmark under new lease agreement

Sanofi-aventis, Regeneron sign agreement to expand development collaboration

Sanofi-aventis, Regeneron sign agreement to expand development collaboration

BioMed Realty Trust reports increased revenues of $93.0 million for the third quarter

BioMed Realty Trust reports increased revenues of $93.0 million for the third quarter